Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) was up 1.7% during trading on Wednesday . The company traded as high as $35.34 and last traded at $34.96, with a volume of 888,162 shares changing hands. The stock had previously closed at $34.36.

A number of equities research analysts have recently commented on ACAD shares. Zacks Investment Research cut shares of Acadia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Leerink Swann cut shares of Acadia Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $40.00 to $35.00 in a report on Tuesday, May 3rd. Cowen and Company reiterated an “outperform” rating and set a $41.00 price target on shares of Acadia Pharmaceuticals in a report on Thursday, May 5th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $44.00 price target on shares of Acadia Pharmaceuticals in a report on Thursday, May 5th. Finally, HC Wainwright reiterated a “buy” rating on shares of Acadia Pharmaceuticals in a report on Friday, May 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $45.80.

The stock has a 50 day moving average of $34.42 and a 200 day moving average of $30.18. The company’s market cap is $3.69 billion.

Acadia Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.14. The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $0.71 million. The business’s quarterly revenue was up 96900.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.39) EPS. On average, equities analysts expect that Acadia Pharmaceuticals Inc. will post ($2.15) EPS for the current fiscal year.

In other Acadia Pharmaceuticals news, Director Bros. Advisors Lp Baker purchased 1,303,030 shares of Acadia Pharmaceuticals stock in a transaction dated Wednesday, August 10th. The stock was acquired at an average price of $33.00 per share, for a total transaction of $42,999,990.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Glenn Baity sold 4,057 shares of the business’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $35.00, for a total transaction of $141,995.00. Following the completion of the sale, the executive vice president now owns 66,978 shares of the company’s stock, valued at approximately $2,344,230. The disclosure for this sale can be found here.

Several large investors have bought and sold shares of ACAD. New York State Common Retirement Fund raised its stake in Acadia Pharmaceuticals by 13.6% in the fourth quarter. New York State Common Retirement Fund now owns 95,020 shares of the biopharmaceutical company’s stock valued at $3,387,000 after buying an additional 11,400 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Acadia Pharmaceuticals by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 150,666 shares of the biopharmaceutical company’s stock valued at $5,372,000 after buying an additional 1,739 shares in the last quarter. Morgan Stanley raised its stake in Acadia Pharmaceuticals by 9.3% in the fourth quarter. Morgan Stanley now owns 321,183 shares of the biopharmaceutical company’s stock valued at $11,449,000 after buying an additional 27,260 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new stake in Acadia Pharmaceuticals during the fourth quarter valued at approximately $52,744,000.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.